Picard Medical Inc.
PMI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PMI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMI
Picard Medical Inc. (PMI) is a medical device company with FDA-approved products generating commercial revenue, but it faces significant financial challenges, including a going concern qualification and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Picard Medical Inc..
Picard Medical Inc. (PMI) is a medical device company with FDA-approved products generating commercial revenue, but it faces significant financial challenges, including a going concern qualification and a history of operating losses.
- Picard Medical has incurred operating losses since inception, with net losses of $27.0 million and $21.1 million for the years ended December 31, 2025 and 2024, respectively [sec · filed 2026-05-20].
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern due to significant working capital deficiency and recurring losses [sec · filed 2026-05-20].
- As of the latest reported financials (2026-06-30), Picard Medical had cash & equivalents of $0.0M, total revenue of $3.0M, net income of -$5.7M, and shareholders' equity of -$48.9M [sec].
- The company's future success depends on developing, obtaining regulatory approval for, and commercializing new products or product enhancements, including a long-term indication [sec · filed 2026-05-20].
- A small number of customers or key surgeons account for a substantial portion of revenues, and sales are not based on long-term committed-volume purchase contracts [sec · filed 2026-05-20].
What works
- Picard Medical has FDA-approved products that are generating commercial revenue, providing a base for scaling the business [sec · filed 2026-05-20].
- The company has an established product, the SynCardia TAH, with ongoing clinical studies that could support future regulatory approvals or label expansions [sec · filed 2026-05-20].
What to weigh
- The company has a going concern qualification from its independent auditor, indicating substantial doubt about its ability to continue operating [sec · filed 2026-05-20].
- Picard Medical has a history of operating losses and expects to continue incurring losses for the foreseeable future, with no near-term profitability anticipated [sec · filed 2026-05-20].
- The company relies on a small number of customers for a substantial portion of its revenue, and there are no long-term committed-volume purchase contracts, creating revenue volatility [sec · filed 2026-05-20].
- The company faces significant risks in obtaining regulatory approvals for new products or product enhancements, and clinical trials may be delayed or fail [sec · filed 2026-05-20].
From the filings
Quoted directly from source documents.
The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
“The report from our independent registered public accounting firm for the years ended December 31, 2025, and 2024, includes an explanatory paragraph stating that we have significant working capital deficiency, and have incurred operating losses since inception. These conditions raise substantial doubt about our ability to continue as a going concern.”
SEC filings · May 20, 2026
The company has incurred operating losses since inception and expects to continue losing money.
“We have incurred operating losses since inception, including net losses of $27.0 million and $21.1 million for the years ended December 31, 2025 and 2024, respectively.”
SEC filings · May 20, 2026
A small number of customers account for a substantial portion of revenues.
“A small number of customers or key surgeons account for a substantial portion of our revenues.”
SEC filings · May 20, 2026
The company's future depends on developing and obtaining regulatory approval for new products.
“Our future success depends on our ability to develop, receive regulatory approval (including long term indication) for, and introduce new products or product enhancements that will be accepted by the market in a timely manner.”
SEC filings · May 20, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditor has expressed substantial doubt about the company's ability to continue as a going concern due to working capital deficiency and operating losses [sec · filed 2026-05-20].
- Customer concentration — A small number of customers or key surgeons account for a substantial portion of revenues, with no long-term contracts [sec · filed 2026-05-20].
- Regulatory approval risk — Obtaining FDA approval for new products or enhancements is uncertain, expensive, and subject to delays or failure [sec · filed 2026-05-20].
- History of losses — The company has incurred operating losses since inception and does not anticipate profitability in the near future [sec · filed 2026-05-20].
What to watch
- Ability to raise additional capital or financing to fund operations and address the going concern [sec · filed 2026-05-20].
- Progress and results of clinical studies for the SynCardia TAH and other products [sec · filed 2026-05-20].
- Regulatory decisions on new product approvals or label expansions, including a long-term indication [sec · filed 2026-05-20].
- Revenue trends and customer concentration, particularly any changes in orders from key customers [sec · filed 2026-05-20].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Picard Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Picard Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.3 months
D/E 4.34
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$454K
| Holder | Shares | Value |
|---|---|---|
| eversource wealth advisors, llc | 997 | $88K |
| state street corp | 83,751 | $87K |
| geode capital management, llc | 59,578 | $62K |
| aqr capital management llc | 55,262 | $57K |
| vanguard portfolio management llc | 30,208 | $31K |
| northern trust corp | 17,927 | $19K |
| new york state common retirement fund | 17,892 | $19K |
| charles schwab investment management inc | 16,130 | $17K |
| blackrock, inc. | 13,489 | $14K |
| hudson bay capital management lp | 10,614 | $11K |
Showing top 10 of 39 institutional holders of Picard Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 12, 2026- % of float
- 2.1%
- Days to cover
- 4.3
- Shares short
- 594,449
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Picard Medical Inc.?
Picard Medical Inc. (PMI) is a medical device company with FDA-approved products generating commercial revenue, but it faces significant financial challenges, including a going concern qualification and a history of operating losses.
What is Picard Medical Inc.'s lead drug candidate?
Picard Medical Inc.'s most advanced tracked candidate is syncardia tah (Approved) for Bridge to heart transplantation (BTT) for patients with biventricular heart failure.
Who is the CEO of Picard Medical Inc.?
Dr. Yuncai Fang Ph.D. is the chief executive officer of Picard Medical Inc. (PMI).
Where is Picard Medical Inc. headquartered?
Picard Medical Inc. (PMI) is headquartered in Tucson, AZ, United States.
What therapeutic areas does Picard Medical Inc. focus on?
Picard Medical Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.